MCRB · Seres Therapeutics, Inc. · Earnings Call Transcripts & Audio
$3.35
-0.13 (-3.74%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“these conditions raise substantial doubt about the Company's ability to continue as a going concern. ... As a result, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 5, 2026
Market Cap
$34.99M
Shares
9.94M
Volume · Sep 30
54.61K
Avg daily vol (3M)
73.92K
Seres Therapeutics, Inc. Earnings Call Transcripts
Quarterly earnings calls for Seres Therapeutics, Inc. (MCRB), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼58.9%
$7.22M
−$50.00M
'21 Q4
22-03-01
▼73.9%
$1.49M
−$56.62M
'22 Q1
22-05-04
▼76.9%
$1.22M
−$64.73M
'22 Q2
22-08-03
▼97.3%
$3.44M
−$60.00M
'22 Q3
22-11-02
▼86.5%
$975,000
−$68.80M
'22 Q4
23-03-07
▼135%
$
−$71.17M
'23 Q1
23-04-27
▲10300.7%
$126.47M
$46.55M
'23 Q2
23-08-08
▼91%
$310,000
−$47.85M
'23 Q3
23-11-02
▼13049.8%
$
−$41.25M
'23 Q4
24-03-05
·
$
−$40.13M
'24 Q1
24-05-08
▼100%
$
−$32.87M
'24 Q2
24-08-13
▼100%
$
$88.78M
'24 Q3
24-11-13
·
$
−$15.64M
'24 Q4
25-03-13
·
$
$32.68M
'25 Q1
25-05-07
·
$
−$19.86M
'25 Q2
25-08-06
LATEST
·
$351,000
$8.20M
'25 Q3
25-11-05
Earnings call
FY25 · Q3
2025-11-05
Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript
Positive tone
Investigator-sponsored IREC study at MSK
Capital needs and funding dependency
CARB-X non-dilutive funding and oral liquid formulation
Revenue
$351,000
Diluted EPS
$0.94
▼ 91.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript
Positive tone
CER155 Phase II development and design
FDA engagement and regulatory progress
Capital and business development needs
Revenue
$
Diluted EPS
$-2.27
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript
Positive tone
SER-155 Phase 2 Study Design and Timeline
FDA Interaction and Regulatory Path
Clinical Data and Translational Evidence
Revenue
$
Diluted EPS
$3.75
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-13
Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript
Positive tone
SER-155 clinical progress and BSI risk reduction
FDA engagement and breakthrough therapy designation
Exploratory biomarker data and mechanism of action
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript
Confident tone
SER-155 clinical results and pipeline
VOWST sale to Nestlé Health Science
Partnership strategy for SER-155
Revenue
$
▼ 100% YoY Diluted EPS
$11.63
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript
Positive tone
SER-155 Phase Ib Cohort 2 readout
SER-147 program in metabolic disease
Corporate restructuring and pipeline focus
Revenue
$
▼ 100% YoY Diluted EPS
$-4.34
▼ 160.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript
Balanced tone
VOWST Commercial Launch
Nestle Partnership & Launch Refinements
SER-155 Clinical Program
Revenue
$
Diluted EPS
$-5.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-05
Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript
Positive tone
VOWST launch and commercial performance
SER-155 clinical readout and pipeline
Hospital outflow and HCP adoption
Revenue
$*
▼ 13049.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript
Revenue
$310,000
▼ 91% YoY Diluted EPS
$-7.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Seres Therapeutics, Inc. (MCRB) Q2 2023 Earnings Call Transcript
Revenue
$126.47M
▲ 10300.7% YoY Diluted EPS
$7.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
Seres Therapeutics, Inc. (MCRB) Q1 2023 Earnings Call Transcript
Revenue
$
▼ 135% YoY Diluted EPS
$-11.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Seres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call Transcript
Revenue
$975,000*
▼ 86.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Seres Therapeutics, Inc. (MCRB) Q3 2022 Earnings Call Transcript
Revenue
$3.44M
▼ 97.3% YoY Diluted EPS
$-9.80
▼ 168.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Seres Therapeutics, Inc. (MCRB) Q2 2022 Earnings Call Transcript
Revenue
$1.22M
▼ 76.9% YoY Diluted EPS
$-14.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Seres Therapeutics, Inc. (MCRB) Q1 2022 Earnings Call Transcript
Revenue
$1.49M
▼ 73.9% YoY Diluted EPS
$-12.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Seres Therapeutics, Inc. (MCRB) Q4 2021 Earnings Call Transcript
Revenue
$7.22M*
▼ 58.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Seres Therapeutics, Inc. (MCRB) Q3 2021 Earnings Call Transcript
Revenue
$126.72M
▲ 8843.2% YoY Diluted EPS
$14.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Seres Therapeutics, Inc. (MCRB) Q2 2021 Earnings Call Transcript
Revenue
$5.26M
▼ 12.9% YoY Diluted EPS
$-10.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Seres Therapeutics, Inc. (MCRB) Q1 2021 Earnings Call Transcript
Revenue
$5.72M
▼ 30.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-02
Seres Therapeutics, Inc. (MCRB) Q4 2020 Earnings Call Transcript
Revenue
$17.56M*
▲ 130.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Seres Therapeutics, Inc. (MCRB) Q3 2020 Earnings Call Transcript
Revenue
$1.42M
▼ 79.8% YoY Diluted EPS
$-7.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Seres Therapeutics, Inc. (MCRB) Q1 2020 Earnings Call Transcript
Revenue
$8.19M
▲ 11.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-02
Seres Therapeutics, Inc. (MCRB) Q4 2019 Earnings Call
Revenue
$7.62M*
▼ 28.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–23 of 23 earnings calls